Evaluation of safety and efficacy of drug loaded microspheres via pulmonary artery and bronchial artery infusion chemoembolization in the treatment of advanced non-small cell lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041032

Enrollment

Unknown

Registered

2020-12-16

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

BACE:Bronchial artery chemoembolization

TPCE:Pulmonary arterial chemoembolization

BACE+TPCE:Bronchial artery chemoembolization+Pulmonary arterial chemoembolization

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Non small cell lung cancer confirmed by pathology,with clinical stage IIIb or IV; 2) Aged < 80 years; 3) Initial treatment patients; 4) Refusal or failure of standard chemotherapy, radiotherapy and targeted therapy; 5) ECOG <= 2,The expected survival time was more than 8 months,The subjects participated voluntarily and informed consent was signed.

Exclusion criteria

Exclusion criteria: 1) Uncontrolled extrapulmonary metastases, including intracranial, liver and bone metastases; 2) There were other malignant tumors; 3) White blood cell count 2.0 mg / L); 6) Coagulation dysfunction (INR > 1.5) or hemorrhagic disease or anticoagulant therapy is in progress; 7) Pregnancy or lactation; 8) Allergy to radiography agent.

Design outcomes

Primary

Measure	Time frame
Progression free survival;	—

Secondary

Measure	Time frame
Side effects of drugs;Operation related complications;Overall survival;	—

Countries

China

Contacts

Public ContactWei Luo

People's Hospital of Leshan

451188923@qq.com+86 13881330125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026